Adebrelimab
Adding VEGF tyrosine kinase inhibitors to PD-1/PD-L1 inhibitors and chemotherapy increases objective response rates to 35–80% in phase II studies. The TOPAZ-1 and KEYNOTE-966 trials established that PD-1/PD-L1 inhibitors combined with chem…
1 sources - 3 claims
Adding VEGF tyrosine kinase inhibitors to PD-1/PD-L1 inhibitors and chemotherapy increases objective response rates to 35–80% in phase II studies. The TOPAZ-1 and KEYNOTE-966 trials established that PD-1/PD-L1 inhibitors combined with chemotherapy produce objective response rates of 25–30% in advanced biliary tract carcinoma. Adebrelimab acts by blocking PD-L1 to reactivate T-cell antitumor responses.